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Unexpected Reaction Pathway for 
butyrylcholinesterase-catalyzed 
inactivation of “hunger hormone” 
ghrelin
Jianzhuang Yao1,2, Yaxia Yuan1,2, Fang Zheng1,2 & Chang-Guo Zhan1,2
Extensive computational modeling and simulations have been carried out, in the present study, to 
uncover the fundamental reaction pathway for butyrylcholinesterase (BChE)-catalyzed hydrolysis of 
ghrelin, demonstrating that the acylation process of BChE-catalyzed hydrolysis of ghrelin follows an 
unprecedented single-step reaction pathway and the single-step acylation process is rate-determining. 
The free energy barrier (18.8 kcal/mol) calculated for the rate-determining step is reasonably close 
to the experimentally-derived free energy barrier (~19.4 kcal/mol), suggesting that the obtained 
mechanistic insights are reasonable. The single-step reaction pathway for the acylation is remarkably 
different from the well-known two-step acylation reaction pathway for numerous ester hydrolysis 
reactions catalyzed by a serine esterase. This is the first time demonstrating that a single-step reaction 
pathway is possible for an ester hydrolysis reaction catalyzed by a serine esterase and, therefore, one 
no longer can simply assume that the acylation process must follow the well-known two-step reaction 
pathway.
Obesity is well known as a major public health problem, and it is related to the worldwide increasing rates of the 
disease and burden of the associated co-morbidities, such as type 2 diabetes, cardiovascular disease, and cancer1. 
More than one third of adult population in the world are reported to be in the risk of overweight-caused diseases, 
e.g. diabetes mellitus, hypertension, coronary heart disease, stroke, gall bladder disease, osteoarthritis, and dys-
lipidaemia2–4. It is crucial for improving health of people in the risk of overweight-caused diseases to lose weight. 
Unfortunately, caloric restriction (e.g. fasting) is commonly accompanied by elevated appetite5, which makes 
weight loss a great challenge for obese individuals. In fact, more than 30 billion dollars were spent annually in the 
United States on reduced-calorie and multitudinous diets6. However, such diets did not show significant efficacy 
in weight loss7.
An effective pharmacological treatment is needed to counteract the increased appetite during fasting. 
However, FDA-approved pharmaceutical agents for obesity treatment are accompanied by serious adverse/toxic 
effects and, thus, a number of pharmaceutical agents (e.g. aminorex, dexfenfluramine, fenfluramine, and phenyl-
propanolamine) have been withdrawn from the market8,9. Currently available FDA-approved anti-obesity drugs 
include phentermine, lorcaserin, orlistat, and phentermine/topiramate ER, still with a variety of adverse side 
effects, such as insomnia, headache, diarrhea, dizziness, depression, and many others10. It is highly desired to 
develop a new, safe, and truly effective pharmacological agent for obesity treatment.
Interestingly, a gastric peptide hormone, known as ghrelin or the “hunger hormone”, was discovered in 1999 
by Kojima et al.11. Ghrelin is a 28-amino acid peptide (GSSFLSPEHQKAQQRKESKKPPAKLQPR) with Ser3 side 
chain acylated by a fatty acid (n-octanoic acid), as shown in Fig. 1A. So, ghrelin has an n-octanoylated peptide. 
The 28-amino acid peptide without acylation (n-octanoylation) is known as desacyl-ghrelin12. This acylation, via 
ghrelin O-acyltransferase enzyme (GOAT), is essential for the activity of ghrelin with growth hormone secreta-
gogue receptors (GHSRs) in the central nervous system (CNS) that mediate hyperphagia and adiposity13. Ghrelin 
was identified in human stomach. It is believed that ghrelin is released primarily from cells in the stomach and 
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travels to the brain through blood circulation. In the brain, ghrelin interacts with both hypothalamus (the brain’s 
physiological eating center) and the brain’s pleasure centers to arouse hunger14. In fact, ghrelin is the only known 
hormone stimulating hunger and food intake1, telling you when to eat. Ghrelin level naturally changes dramat-
ically during the course of a day. Ghrelin level rises steeply with fasting (or before a meal) and decreases after a 
meal14. Ghrelin is emerging as a novel, potentially attractive anti-obesity drug target8.
Recent drug discovery efforts have been centralized on ghrelin and aim to reduce the appetite of overweight 
people by different approaches, including regulation of ghrelin release, ghrelin receptor antagonism, and reducing 
active ghrelin production by inhibition of GOAT15–19. However, there is still no clinically useful drug identified 
so far.
Based on the aforementioned physiological and biological mechanisms of ghrelin, an ideal therapeutic 
approach would directly inactivate ghrelin itself and convert ghrelin to its inactive form (desacyl-ghrelin) by 
using an efficient ghrelin-metabolizing enzyme (if available). For example, inhibition of GOAT would decrease 
the production of (active) ghrelin, but cannot inactivate ghrelin that has already generated in the body. A 
ghrelin-metabolizing enzyme would directly inactivate ghrelin by converting ghrelin to desacyl-ghrelin and, 
thus, more effectively decrease the appetite. Despite of extensive effort that aims to regulate the ghrelin level in the 
body, there is no report of a therapeutic candidate which can be used to directly inactivate ghrelin by converting 
ghrelin to desacyl-ghrelin.
More recently reported studies have shed light on the possibility of ghrelin hydrolysis in human butyrylcho-
linesterase (BChE). It was first reported that ghrelin can be hydrolyzed to the inactive form, i.e. desacyl-ghrelin, 
by BChE20, but the enzyme activity was not characterized, without knowing the kinetic parameters for 
BChE-catalyzed ghrelin hydrolysis. Lockridge et al.21 demonstrated that the BChE knockout mice became over-
weight on a high-fat diet compared to the control mice, suggesting that BChE is essential for ghrelin inactivation. 
Most recently reported studies22,23 provided more convincing evidence for the role of human BChE in hydrolyz-
ing ghrelin to desacyl-ghrelin, and the catalytic parameters for BChE-catalyzed hydrolysis of ghrelin were esti-
mated (kcat = ~1.4 min−1 and KM = ~1 μM)22. Obviously, with kcat = ~1.4 min−1, the catalytic activity of wild-type 
BChE against ghrelin is rather low. It is highly desired for development of a novel, safe and effective anti-obesity 
drug to design a mutant of human BChE with a significantly improved catalytic activity against ghrelin.
Here we propose, for the first time, that a BChE mutant with significantly improved catalytic activity against 
ghrelin could be used as an exogenous enzyme to control appetite and for anti-obesity treatment. Human BChE is 
an ideal protein scaffold to develop a therapeutic enzyme, because it has been proven safe for use as an exogenous 
enzyme in humans, and it has the highly desired thermal stability of a therapeutic protein. In a relevant effort, 
starting from computational study of the reaction pathway for BChE-catalyzed hydrolysis of cocaine24, we have 
successfully designed and discovered BChE mutants with considerably improved catalytic activity against cocaine 
for the purpose of developing an enzyme therapy for treatment of cocaine abuse25–32. In fact, one of our designed 
and discovered BChE mutants is currently under Phase II clinical trial for cocaine addiction treatment by Teva 
Pharmaceuticals33–35. The similar computational strategy used to develop an anti-cocaine enzyme therapy may be 
used to develop an anti-obesity enzyme therapy.
For rational design of a BChE mutant with improved catalytic activity against ghrelin, one must first uncover 
and understand the detailed reaction pathway and the corresponding free energy profile for BChE-catalyzed 
Figure 1. Possible reaction pathways for human BChE-catalyzed hydrolysis of ghrelin. (A) Amino acid 
sequence of human ghrelin. (B) Acylation process (with or without existence of a tetrahedral intermediate) 
in which ghrelin is represented as CH3(CH2)6COOR: Reactant State (RS), Tetrahedral Intermediate (TIa), and 
Acyl-Enzyme (AE) + desacyl-ghrelin (ROH). (C) Deacylation process: Acyl-Enzyme (AE) + H2O, Tetrahedral 
Intermediate (TId), and Product State (PS).
www.nature.com/scientificreports/
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hydrolysis of ghrelin, as we did for BChE-catalyzed hydrolysis of cocaine24. So, as the first step of a long-term 
effort towards rational design and discovery of a highly active BChE mutant against ghrelin, this computational 
study aimed to uncover the fundamental reaction pathway for BChE-catalyzed hydrolysis of ghrelin by perform 
quantum mechanical/molecular mechanical (QM/MM) reaction-coordinate calculations, molecular dynamics 
(MD) and free energy simulations. Based on the calculations and simulations, BChE-catalyzed hydrolysis of 
ghrelin follows a unique reaction pathway which is remarkably different from the usual reaction pathway known 
for all ester hydrolysis reactions catalyzed by an esterase such as acetylcholinesterase (AChE), BChE, or any other 
serine esterase. As well-known, an enzymatic ester hydrolysis consists of acylation and deacylation processes 
(as shown in Fig. 1B,C). According to the well-known usual reaction pathway, the acylation stage of the ester 
hydrolysis is a two-step process with a tetrahedral intermediate between two transition states. Surprisingly, for 
BChE-catalyzed hydrolysis of ghrelin, the acylation is a single-step process according to our calculations and 
simulations, and this single-step acylation process is rate-determining. The free energy barrier calculated for 
the rate-determining step is in good agreement with available experimental kinetic data. The novel mechanistic 
insights obtained from this computational study should be valuable not only in guiding future rational design 
and discovery of BChE mutants with improved catalytic activity against ghrelin, but also in future studies on cat-
alytic mechanisms of many other enzymatic ester hydrolysis reactions as it has shown that a single-step acylation 
pathway is possible.
Results
BChE-ghrelin binding mode. The MD simulations at the QM/MM(SCC-DFTB:CHARMM27) level, in 
which the QM calculation was performed at the self-consistent charge density functional tight-binding (SCC-
DFTB) level36 while the MM calculation was performed using the CHARMM27 force field37, revealed that the 
first four residues of ghrelin occupy the active site of human BChE very well. The key catalytic residues of BChE 
include the catalytic triad (consisting of Ser198, His438, and Glu325) and oxyanion hole (consisting of the 
backbone NH groups of Gly116, Gly117, and Ala199). According to the simulated structure (see Figure S1 in 
Supporting Information), the hydroxyl oxygen on the Ser198 side chain of BChE aligns well with the carbonyl 
carbon on the n-octanoylated Ser3 side chain of ghrelin, ready for nucleophilic attack. Meanwhile, the carbonyl 
oxygen of the n-octanoylated Ser3 side chain of ghrelin stays in the oxyanion hole, forming hydrogen bonds with 
the backbone NH groups of Gly117 and Ala199. In addition to the catalytic residues, N-terminal ammonium 
group of ghrelin forms a cation-π interaction with Trp82 of BChE and a salt bridge with Asp197 side chain. 
The hydroxyl group on the side chain of Ser2 of ghrelin forms a hydrogen bond with the oxygen atom of His438 
backbone. The Phe4 side chain of ghrelin locates in a hydrophobic cave formed by Ala328, Phe329, Tyr332, and 
Tyr430. These favorable interactions help to stabilize ghrelin binding in the active site of BChE.
Acylation reaction pathway. Starting from the BChE-ghrelin binding structure (Michaelis-Menten 
complex) as the reactant state (RS depicted in Fig. 1), we performed the QM/MM reaction-coordinate cal-
culations at both the QM/MM(SCC-DFTB:CHARMM27) and QM/MM(B3LYP/6-31G*:CHARMM27) 
levels in which the QM calculation was performed at the SCC-DFTB or B3LYP/6-31G* level while the MM 
calculation was carried out using the CHARMM27 force field. In addition, all geometries optimized at the QM/
MM(B3LYP/6-31G*:CHARMM27) level were used to perform further single-point energy calculations at the 
QM/MM(B3LYP/6-311+ + G**:CHARMM27) level. The QM/MM calculations using different reaction coor-
dinates at various QM/MM levels consistently revealed that the acylation of human BChE with ghrelin is a 
single-step reaction process, as shown in Fig. 2 (and figures in Supporting Information). The acylation process 
is mainly reflected by the formation of a new covalent bond (C− Oγ) between the carbonyl carbon (C) on the 
n-octanoylated Ser3 side chain of ghrelin and the hydroxyl oxygen (Oγ) on Ser198 side chain of BChE and break-
ing of a covalent bond (C− O3) between the carbonyl carbon (C) and the ester oxygen (O3) on the n-octanoylated 
Ser3 side chain of ghrelin. Hence, a linear combination of these two bond lengths, r(C− O3) – r(C− Oγ), was used 
as the reaction coordinate (RC), denoted as RC1 for convenience, for the QM/MM reaction-coordinate calcula-
tions. In further intrinsic reaction coordinate (IRC) calculations at the QM/MM(SCC-DFTB:CHARMM27) level 
starting from the optimized transition state (TS1) structure, TS1 smoothly went to the acyl-enzyme (AE) in the 
forward direction and the reactant state (RS) in the backward direction, which supports that there is only one 
transition state between RS and AE.
According to the QM/MM reaction-coordinate calculations, starting from the RS (Fig. 2A), the acylation pro-
cess involves only one transition state (TS1 depicted in Fig. 2B): the nucleophilic attack proceeds as the hydroxyl 
oxygen (Oγ) of Ser198 of BChE gradually approaches the carbonyl carbon (C) on the n-octanoylated Ser3 side 
chain of ghrelin, while the ester oxygen (O3) atom of the n-octanoylated Ser3 side chain gradually leaves the 
carbonyl carbon. Meanwhile, the hydroxyl hydrogen (Hγ) of the n-octanoylated Ser3 side chain gradually leaves 
Oγ and approaches the ester oxygen (O3) atom of the n-octanoylated Ser3 side chain, as seen in Fig. 2D. As seen 
in Fig. 2D, while the O3–Hγ distance, denoted as r(O3–Hγ), becomes shorter and shorter, the distance between 
Hγ and the nitrogen (Nε) atom on His438 side chain of BChE, denoted as r(Nε–Hγ), becomes even shorter ini-
tially prior to reaching TS1 and then becomes longer and longer. The shortest Nε–Hγ distance is ~1.06 Å which 
is slightly longer than a typical N–H bond length. While r(Nε–Hγ) = ~1.06 Å, r(C–O3) = ~1.62 Å and r(C–
Oγ) = ~1.60 Å; these C–O bond lengths are all significantly longer than a typical C–O bond length. So, it would be 
reasonable to say that Hγ first transfers to Nε (but without a truly stable tetrahedral intermediate associated with a 
local minimum on the potential energy surface) and then transfers to O3. As a result, there is only one transition 
state, TS1, in which the C–O3 bond has been partially broken, while the O3–Hγ bond has not yet been formed, 
as seen in Fig. 2B,D. So, it is also reasonable to say that the nucleophilic attack and the ester oxygen leaving are a 
concerted process (see Fig. 2C) which produces the acylated enzyme or acyl-enzyme (AE): n-octanoylated BChE. 
This concerted single-step acylation process is remarkably different from the well-known two-step acylation 
www.nature.com/scientificreports/
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pathway (associated with an assumed tetrahedral intermediate, like TIa indicated in Fig. 1, sandwiched by two 
transition states) known for numerous enzymatic ester hydrolysis reactions. For comparison and validation, we 
also tested the QM/MM reaction-coordinate calculations using an alternative RC (see Supporting Information), 
leading to the same conclusion that the assumed two-step pathway does not exist for BChE-catalyzed hydrolysis 
of ghrelin because the assumed tetrahedral intermediate is unstable.
According to this novel reaction pathway, in going from RS to TS1, the O…H distances involved in the hydro-
gen bonds between the oxyanion hole and carbonyl oxygen on the n-octanoylated Ser3 side chain of ghrelin 
all become significantly shorter in TS1, as seen in Fig. 2A,B. The enhanced hydrogen bonding helps to stabilize 
transition state TS1. Notably, there is no proton transfer between His438 and Glu325 within the catalytic triad 
during the acylation process.
In order to further validate the SCC-DFTB and B3LYP based QM/MM results, additional QM/MM 
reaction-coordinate calculations were performed on the acylation process by using the more recently developed 
B97-3 functional38 or ω M06-D3 functional39, instead of the B3LYP functional in the QM/MM calculations. 
Depicted in Figure 6S are the potential energy surfaces obtained from the QM/MM reaction-coordinate cal-
culations at the QM/MM(B97-3/6-31G* :CHARMM27) and QM/MM(ω M06-D3/6-31G*:CHARMM27) levels 
and the corresponding single-point energy calculations at the QM/MM(B97-3/6-311+ + G**:CHARMM27) and 
QM/MM(ω M06-D3/6-311+ + G**:CHARMM27) levels. Comparing the data in Figure S6 with those in Figure 
S5, one can see that the three different DFT methods consistently led to the same conclusion that the acylation is 
a single-step reaction process. These additional QM/MM calculations support the reliability of the SCC-DFTB 
and B3LYP based QM/MM calculations.
Further, the combined QM/MM(SCC-DFTB:CHARMM27) MD and potential of mean force (PMF) simu-
lations were carried out to simulate the acylation reaction process, accounting for the dynamics of the reaction 
process, and determine two-dimensional (2D) free energy maps associated with two different RC’s. The obtained 
2D free energy maps (see Figure S2 in Supporting Information) for the acylation process demonstrate that the 
local minimum associated with pre-assumed tetrahedral intermediate TIa indeed does not exist on the 2D free 
Figure 2. Optimized geometries of (A) the reactant state (RS) and (B) the transition state (TS1) for the 
acylation process of BChE-catalyzed hydrolysis of ghrelin. Indicated in the figures are the internuclear distances 
(Å) optimized at the QM/MM(SCC-DFTB:CHARMM27) level, and the values in parentheses refer to the 
distances optimized at the QM/MM(B3LYP/6-31G*:CHARMM27) level. (C) Plot of the potential energy 
vs the reaction coordinate (RC1) used the in the QM/MM(SCC-DFTB:CHARMM27) reaction-coordinate 
calculations; RC1 = r(C− O3) – r(C− Oγ). (D) Plots of key internuclear distances vs the intrinsic reaction 
coordinate (IRC) calculations at the QM/MM(SCC-DFTB:CHARMM27) level. The distances shown include 
the following atoms: C (carbonyl carbon atom on the n-octanoylated Ser3 side chain of ghrelin); O3 (ester 
oxygen atom on the n-octanoylated Ser3 side chain of ghrelin); Oγ (hydroxyl oxygen atom on Ser198 side chain 
of BChE); Hγ (hydroxyl hydrogen on the n-octanoylated Ser3 side chain of ghrelin); and Nε (nitrogen atom on 
His438 side chain of BChE).
www.nature.com/scientificreports/
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energy maps, and that there is only one transition state (TS1) existing between RS and AE. The 2D free energy 
maps provide further support to the finding that the acylation of human BChE with ghrelin is a single-step reac-
tion process.
Deacylation reaction pathway. Starting from the AE structure, further reaction-coordinate calculations 
were carried out on the deacylation process at the same QM/MM levels used for the acylation process. The calcu-
lations using different reaction coordinates (RC’s) at all QM/MM levels consistently revealed that deacylation of 
AE follows a well-known two-step reaction pathway known for many other enzymatic ester hydrolysis reactions. 
As shown in Figs 1 and 3, during the chemical transformation from the acyl-enzyme (AE) to a tetrahedral inter-
mediate (TId) through transition state TS2, the oxygen (Ow) atom of the nucleophilic water gradually approaches 
the carbonyl carbon (C) atom while a proton (Hw) of the water molecule gradually transfers to the Nε atom of 
His438 side chain. During the next reaction step from TId to the product state (PS depicted in Fig. 1), a proton 
gradually transfers from the nitrogen atom (Nε) atom of His438 side chain to the hydroxyl oxygen (Oγ) atom of 
Ser198 side chain while the covalent bond C− Oγ gradually breaks. In practical QM/MM reaction-coordinate 
calculations leading to the results depicted in Fig. 3, the RC associated with TS2 was r(Ow− Hw) – r(C− Ow) 
– r(Nε− Hw), and the RC associated with TS3 was r(C− Oγ) + r(Nε− Hw) – r(Oγ− Hw). In addition, the QM/
MM(SCC-DFTB:CHARMM27) reaction-coordinate calculations using a uniformed RC, i.e. RC4 = r(C− Oγ) – 
r(C− Ow), led to essentially the same results depicted in Fig. 3. As seen in Fig. 3, there is no proton transfer 
between His438 and Glu325 within the catalytic triad during the deacylation process.
In addition, the combined QM/MM(SCC-DFTB:CHARMM27) MD and PMF simulations were carried out 
to simulate the deacylation process, accounting for the dynamics of the reaction process, and determine 2D free 
energy maps associated with two different RC’s (Figure S3). The obtained 2D free energy maps are consistent with 
the finding that the deacylation process indeed follows the usual two-step reaction pathway known for numerous 
other enzymatic ester hydrolysis reactions.
Overall free energy profile in comparison with available experimental data. Depicted in Fig. 4 
is the minimum free energy profile plotted based on the 2D free energy maps (depicted in Figures S2 and S3). 
According to Fig. 4 and Figure S7, the entire BChE-catalyzed ghrelin hydrolysis process involves only three tran-
sition states (TS1 to 3), rather than the usually assumed four (or more) transition states known for enzymatic 
hydrolysis reactions of many other esters. No stable tetrahedral intermediate is found along the minimum free 
energy path of the acylation process. The free energy barriers associated with the three transition states (TS1 to 3) 
Figure 3. Optimized geometries of (A) the acyl-enzyme (AE) + H2O, (B) transition state TS2, (C) tetrahedral 
intermediate TId, and (D) transition state TS3 during the deacylation process of BChE-catalyzed hydrolysis 
of ghrelin. Indicated in the geometries are the internuclear distances (Å) optimized at the QM/MM(SCC-
DFTB:CHARMM27) level, and the corresponding values in parentheses refer to the distances optimized at the 
QM/MM(B3LYP/6-31G*:CHARMM27) level.
www.nature.com/scientificreports/
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are 18.8 ± 0.1, 16.6 ± 0.5, and 13.3 ± 0.1 kcal/mol, respectively; the error bars were estimated based on the con-
vergence of the PMF simulations with respect to the length of the production MD simulation run for each win-
dow (see Figure S7 in Supporting Information). Thus, the first reaction step (acylation) is rate-determining for 
BChE-catalyzed hydrolysis of ghrelin. The calculated highest free energy barrier of ~18.8 kcal/mol is reason-
ably close to the free energy barrier of ~19.4 kcal/mol derived from the available experimental rate constant 
(kcat = 2.2 min−1)38 according to the conventional transition state theory40, suggesting that the obtained mecha-
nistic insights are reasonable.
Discussion
All of the QM/MM reaction-coordinate calculations, MD and PMF simulations have consistently demon-
strated that the acylation process of BChE-catalyzed hydrolysis of ghrelin follows a single-step reaction path-
way without existence of a stable tetrahedral intermediate between the reactant state (Michaelis-Menten 
complex) and acyl-enzyme, and that the deacylation is a two-step process. The single-step acylation process is 
rate-determining for the enzymatic hydrolysis of ghrelin. The free energy barrier of 18.8 kcal/mol calculated for 
the rate-determining step is reasonably close to the experimentally derived free energy barrier of ~19.4 kcal/mol, 
suggesting that the obtained mechanistic insights are reasonable.
The single-step reaction pathway for the acylation is remarkably different from the well-known two-step acy-
lation reaction pathway for numerous ester hydrolysis reactions catalyzed by a serine esterase. It should be noted 
that the question of whether a tetrahedral intermediate exists at all has been a long discussion for uncatalyzed 
ester hydrolysis41,42. But the discussion has not involved an enzyme for catalysis. This is the first time demonstrat-
ing that a single-step reaction pathway is possible for an ester hydrolysis reaction catalyzed by a serine esterase 
and, therefore, one no longer can simply assume that the acylation process must follow the well-known two-step 
reaction pathway for the enzymatic ester hydrolysis.
In addition, the novel mechanistic insights and the rate-determining transition-state structure obtained in 
this computational study may be used in the future to guide rational design and discovery of a therapeutically 
valuable BChE mutant with improved catalytic efficiency against ghrelin. Generally speaking, for the purpose of 
future rational design of a BChE mutant with improved catalytic activity against ghrelin, it is important to under-
stand why the free energy barrier (18.8 kcal/mol) calculated for the acylation process is significantly higher than 
those (16.6 and 13.3 kcal/mol) calculated for the deacylation process. One of the most crucial factors affecting the 
catalytic rate constant of a serine esterase is the hydrogen bonding between the carbonyl oxygen of the ester to be 
hydrolyzed and the oxyanion hole of the esterase. Such type of hydrogen bonding helps to stabilize the transition 
states and, thus, lower the free energy barriers, because the carbonyl oxygen will generally have more and more 
(partial) negative charge to make the hydrogen bonding stronger and stronger in going from the reactant state 
or acyl-enzyme to the transition state during the initial step of the acylation or deacylation step. In general, the 
overall hydrogen bonding with the carbonyl oxygen is expected to be stronger in the transition state compared 
to that in the reactant state or acyl-enzyme. Specifically for BChE-catalyzed hydrolysis of ghrelin, the carbonyl 
oxygen of the n-octanoylated Ser3 side chain has only two hydrogen bonds with the oxyanion hole of BChE (spe-
cifically with the NH groups of Gly117 and Ala199) during the acylation process, as seen in Fig. 2. The carbonyl 
oxygen has no hydrogen bond with Gly116 of the oxyanion hole. In comparison, the same carbonyl oxygen has 
three hydrogen bonds with all residues of the oxyanion hole, specifically with the NH groups of Gly116, Gly117, 
and A199 during the deacylation process. The difference between the acylation and deacylation in the hydrogen 
bonding is likely one of the possible main reasons for the relatively higher free energy barrier of the acylation 
process. Hence, the focus for further effort to design a BChE mutant with improved catalytic activity against 
ghrelin should aim to identify possible amino-acid mutations (particularly on the amino-acid residues nearby the 
oxyanion hole) that can enhance the overall hydrogen bonding of the carbonyl oxygen with the oxyanion hole, 
including an additional hydrogen bonding with the NH group of Gly116. The similar computational strategy has 
Figure 4. Minimum free energy profile determined by the QM/MM(SCC-DFTB:CHARMM27) 
calculations based two-dimensional PMF free energy maps for the entire reaction process (acylation and 
deacylation) of BChE-catalyzed hydrolysis of ghrelin. 
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successfully been used in our previous studies26,27,32 to virtually screen and computationally design BChE mutants 
with considerably improved catalytic activity against cocaine, demonstrating that mutations on other amino-acid 
residues (that are nearby or far away from the active site) could significantly affect the overall hydrogen bonding 
between the carbonyl oxygen and oxyanion hole and, thus, significantly change the catalytic activity. In light of 
all these insights, we are currently planning a long-term integrated computational-experimental effort, includ-
ing extensive virtual screening of the rate-determining transition-state (TS1) structures associated with a large 
number hypothetical mutants of human BChE and subsequent experimental studies, for rational design and 
discovery of BChE mutants with improved catalytic activity against ghrelin. A BChE mutant with significantly 
improved catalytic activity against ghrelin should be therapeutically valuable for use as an exogenous enzyme in 
obesity treatment.
Methods
Construction of the initial BChE-ghrelin binding structures. Starting from an extended backbone 
conformation of ghrelin, AMBER12 package43 was used to model the structure of free ghrelin molecule in water 
by performing MD simulations for 20 ns. Force-field parameters of the non-standard residues, i.e. n-octanoylated 
Ser3 of ghrelin and caprylic acid, were prepared according to published methods44,45. X-ray crystal structure 
of BChE (PDB code: 1P0I, 2.0 Å resolution)46 and the simulated structure of ghrelin were used to generate the 
initial BChE-ghrelin binding complex structure (reactant state RS). Then the simulated system was prepared 
using a similar protocol described previously47. Briefly, AMBER99SB force field was used to model the protein 
and counter ions (Na+)48. The TIP3P water model was employed for the solvent49. Protonation states of all acidic 
and basic amino-acid residues were determined by surrounding environment under physiological pH condition 
(pH 7.4). Hydrogen atoms were added to the PDB file via the LEAP module of the AMBER12. The system was 
solvated initially with TIP3P water for a minimum distance of 10 Å on each side. The N-terminal amino group of 
ghrelin was manually placed near to the entrance of substrate-binding site for BChE by PyMol50. The AMBER12 
was used to first guide the N-terminal amino group of ghrelin approaching carboxyl group of Glu197 of BChE, 
and then guide the carbonyl carbon on the n-octanoylated Ser3 side chain of ghrelin to approach the hydroxyl 
group on Ser198 side chain of BChE. Next, the carbonyl oxygen of the n-octanoylated Ser3 of ghrelin was guided 
to form hydrogen bonds with backbone hydrogen atoms of residues (e.g. Gly116, Gly117, and Ala199) within the 
oxyanion hole of BChE by using variable distance constraint implemented in the AMBER12 program.
The obtained BChE-ghrelin structure was used as the initial structure for further MD simulations, starting 
from a 10-ns MD simulation with constrained distances related to Ser3 of ghrelin. The constrained MD simula-
tion was followed by a fully relaxed MD simulation for 20 ns to obtain a stable MD trajectory generating a stable 
BChE-ghrelin binding structure. The last snapshot of the MD simulation was selected as the initial structure for 
subsequent Stochastic boundary MD simulation based on the QM/MM method with the QM calculation at the 
SCC-DFTB level36 implemented in the CHARMM program51,52. Specifically, for the QM/MM calculations, the 
water molecules located longer than 22 Å away from the hydroxyl oxygen on Ser198 side chain of BChE were 
deleted from the system. Included in the QM-treated region were the side chains of n-octanoylated Ser3 of ghrelin 
and Ser198, His438, and Glu325 of BChE, and the remaining part of the system was included in the MM-treated 
region. The divided frontier charge (DIV) link-atom scheme52,53 was applied to the QM and MM boundary treat-
ment. The SCC-DFTB method with empirical dispersion corrections54 implemented in the CHARMM55 was used 
for the QM atoms and the all-hydrogen CHARMM potential function (PARAM27)37 was used for the MM atoms. 
Previous computational studies have demonstrated that the SCC-DFTB based QM/MM calculations on esterase 
reactions are realiable56. The resulting system contained around 6000 atoms, including about 300 water molecules. 
No non-bonded interaction truncation cut-off was used in the calculations of QM–MM interactions. Within the 
MM region atoms, the used non-bonded interaction truncation cut-off was 13 Å.
Stochastic boundary MD method57 was used with the oxygen atom (Oγ) of Ser198 side chain as the refer-
ence centre. The reaction region was a sphere with a radius (r) of 20 Å, and the buffer region extended over 
20 Å ≤ r ≤ 22 Å. All bonds involving hydrogen atoms in MM region were constrained by using the SHAKE 
algorithm58. The initial structures for the entire stochastic boundary systems were optimized using the steepest 
descent (SD) and adopted-basis Newton-Raphson (ABNR) methods. A 1-fs time step was used for integration of 
the equation of motion. The system of reactant complex was gradually heated from 50.0 K to 298.15 K in 100 ps 
and then 1.5 ns production run was performed for the BChE-ghrelin complex (reactant state RS).
QM/MM reaction-coordinate calculations. The final RS structure mentioned above was used to perform 
QM/MM reaction-coordinate calculations at the QM/MM(SCC-DFTB:CHARMM27) level in which the QM cal-
culation was performed at the SCC-DFTB level36 while the MM calculation was performed using the CHARMM27 
force field37 implemented in the CHARMM program. Further, for validation, the QM/MM reaction-coordinate 
calculations were also carried out at the QM/MM(B3LYP/6-31G*:CHARMM27) level in which the QM calcula-
tion was performed at the B3LYP/6-31G* level while the MM calculation was carried out using the CHARMM27 
force field. In addition, the geometry optimization at the QM/MM(B3LYP/6-31G*:CHARMM27) level was fol-
lowed by single-point energy calculation at the QM/MM(B3LYP/6-311+ + G**:CHARMM27) level, which may 
be denoted as the QM/MM(B3LYP/6-311+ + G**:CHARMM27)//QM/MM(B3LYP/6-31G*:CHARMM27) level 
for convenience. Our previous QM/MM calculations on BChE-involved enzyme reactions59–66 revealed that these 
QM levels (B3LYP/6-31G* for geometry optimization and B3LYP/6-311+ + G** for subsequent single-point 
energy calculations) are adequate for the QM/MM calculations on these enzymatic reaction systems.
The QM/MM reaction-coordinate calculations were also carried out using the B97-3 functional38 or 
ω M06-D3 functional39, instead of the B3LYP functional, at the QM/MM(B97-3/6-31G*:CHARMM27) and 
QM/MM(ω M06-D3/6-31G*:CHARMM27) levels, followed by the single-point energy calculations at the 
QM/MM(B97-3/6-311+ + G**:CHARMM27) or QM/MM(ω M06-D3/6-311+ + G**:CHARMM27) level. The 
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QM/MM calculations with the B3LYP or B97-3 were carried out by using the GAMESS-US program67 interfaced 
with the CHARMM program51,52, and the ω M06-D3-based QM/MM calculations were carried out by using the 
QCHEM program68 interfaced with the CHARMM program69.
Reaction coordinates (RC’s) used in the QM/MM reaction-coordinate calculations were defined as linear com-
binations of key internuclear distances involved in the reaction process. The potential energy surface was gener-
ated by the adiabatic mapping calculations starting from the last snapshot of QM/MM(SCC-DFTB:CHARMM27) 
MD simulation on the reactant state (RS) for acylation or acyl-enzyme (AE) for deacylation. The adiabatic map-
ping calculations at all QM/MM levels were carried out using a uniformed protocol. Specifically, a harmonic 
constraint with force constant of 10000 kcal mol−1 Å−2 was added to the RC to guide the BChE acylation and 
deacylation reaction processes. The RC value was increased stepwise along the reaction path (from RS to AE for 
acylation or from AE to PS for deacylation), with a step size of 0.2 Å. An ABNR minimization was carried out 
under the constraint. The RC value then decreased from the product to the reactant. The forward and backward 
progresses were repeated until obtaining a smooth and more reliable potential energy surface profile along the 
reaction path.
In addition, forward and backward intrinsic reaction coordinate (IRC) calculations were also carried out at 
the QM/MM(SCC-DFTB:CHARMM27) level starting from the optimized TS1 geometry associated with the 
first-order saddle point on the potential energy surface, in order to make sure that the first-order saddle point 
associated with TS1 indeed directly connects with the two local minima associated with RS and AE on the poten-
tial energy surface.
Potential mean force (PMF) free energy simulation. The PMF free energy simulation was based on the 
aforementioned QM/MM(SCC-DFTB:CHARMM27) MD simulations. The umbrella sampling method70 imple-
mented in the CHARMM program along with the Weighted Histogram Analysis Method (WHAM)71 was used 
to determine the change of the 2D free energy (PMF) surface as a function of the reaction coordinate. The 2D 
potential energy maps were first generated for both the acylation and deacylation processes by adiabatic mapping 
calculations starting from the last snapshot of the QM/MM(SCC-DFTB:CHARMM27) MD simulation on the 
reaction system. For the 2D free energy maps (including the acylation and deacylation processes), a total of more 
than four-hundred windows were used and, for each window, 100 ps MD simulation was performed with 50 ps 
for equilibration. 80ps MD simulation with 50 ps for equilibration was applied for error bar analysis purpose. The 
force constant of the harmonic biasing potential used in all of the 2D PMF simulations was 150 kcal mol−1 Å−2.
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